Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Jaïs X[au]:

Pulmonary veno-occlusive disease. Montani D et al. Eur Respir J. (2016)

Targeted therapies in pulmonary arterial hypertension. Montani D et al. Pharmacol Ther. (2014)

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Boucly A et al. Eur Respir J. (2017)

Search results

Items: 1 to 50 of 176

1.

Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension.

Seferian A, Jaïs X, Savale L, Jevnikar M, Ghigna MR, Weatherald J, Assoun S, Fadel E, Simonneau G, Sitbon O, Humbert M, Montani D.

Respir Med Res. 2019 Jul 9;76:48-53. doi: 10.1016/j.resmer.2019.06.002. [Epub ahead of print]

PMID:
31557688
2.

Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease.

Savale L, Habibi A, Lionnet F, Maitre B, Cottin V, Jais X, Chaouat A, Artaud-Macari E, Canuet M, Prevot G, Chantalat-Auger C, Montani D, Sitbon O, Galacteros F, Simonneau G, Parent F, Bartolucci P, Humbert M.

Eur Respir J. 2019 Sep 19. pii: 1900585. doi: 10.1183/13993003.00585-2019. [Epub ahead of print]

PMID:
31537700
3.

Screening for pulmonary arterial hypertension in systemic sclerosis.

Weatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M.

Eur Respir Rev. 2019 Jul 31;28(153). pii: 190023. doi: 10.1183/16000617.0023-2019. Print 2019 Sep 30.

4.

Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension.

Taniguchi Y, Jaïs X, Jevnikar M, Boucly A, Weatherald J, Brenot P, Planche O, Parent F, Savale L, Fadel E, Montani D, Humbert M, Sitbon O, Simonneau G.

J Heart Lung Transplant. 2019 Aug;38(8):833-842. doi: 10.1016/j.healun.2019.04.006. Epub 2019 Apr 27.

PMID:
31103383
5.

French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Brenot P, Jaïs X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot S, Mercier O, Fabre D, Parent F, Jevnikar M, Montani D, Savale L, Sitbon O, Fadel E, Humbert M, Simonneau G.

Eur Respir J. 2019 May 18;53(5). pii: 1802095. doi: 10.1183/13993003.02095-2018. Print 2019 May.

PMID:
31023842
6.

Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients.

Picard V, Guitton C, Thuret I, Rose C, Bendelac L, Ghazal K, Aguilar-Martinez P, Badens C, Barro C, Bénéteau C, Berger C, Cathébras P, Deconinck E, Delaunay J, Durand JM, Firah N, Galactéros F, Godeau B, Jaïs X, de Jaureguiberry JP, Le Stradic C, Lifermann F, Maffre R, Morin G, Perrin J, Proulle V, Ruivard M, Toutain F, Lahary A, Garçon L.

Haematologica. 2019 Aug;104(8):1554-1564. doi: 10.3324/haematol.2018.205328. Epub 2019 Jan 17.

7.

Chronic thromboembolic pulmonary hypertension.

Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801915. doi: 10.1183/13993003.01915-2018. Print 2019 Jan.

8.

Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.

Turpin M, Chantalat-Auger C, Parent F, Driss F, Lionnet F, Habibi A, Maître B, Huertas A, Jaïs X, Weatherald J, Montani D, Sitbon O, Simonneau G, Galactéros F, Humbert M, Bartolucci P, Savale L.

Eur Respir J. 2018 Oct 10;52(4). pii: 1800272. doi: 10.1183/13993003.00272-2018. Print 2018 Oct.

PMID:
30305330
9.

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.

Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, Dauphin C, Chaouat A, Savale L, Jaïs X, Jevnikar M, Traclet J, De Groote P, Simonneau G, Hachulla E, Mouthon L, Montani D, Humbert M, Sitbon O.

Eur Respir J. 2018 Oct 18;52(4). pii: 1800678. doi: 10.1183/13993003.00678-2018. Print 2018 Oct.

PMID:
30209196
10.

Pulmonary hypertension associated with neurofibromatosis type 1.

Jutant EM, Girerd B, Jaïs X, Savale L, O'Connell C, Perros F, Sitbon O, Humbert M, Montani D.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180053. doi: 10.1183/16000617.0053-2018. Print 2018 Sep 30. Review.

11.

Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Chaumais MC, O'Connell C, Savale L, Guignabert C, Perros F, Jaïs X, Sitbon O, Humbert M, Montani D.

Int J Clin Pharm. 2018 Aug;40(4):790-794. doi: 10.1007/s11096-018-0712-y. Epub 2018 Aug 13.

PMID:
30101375
12.

Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery.

Amsallem M, Guihaire J, Arthur Ataam J, Lamrani L, Boulate D, Mussot S, Fabre D, Taniguchi Y, Haddad F, Sitbon O, Jais X, Humbert M, Simonneau G, Mercier O, Brenot P, Fadel E.

J Heart Lung Transplant. 2018 Sep;37(9):1102-1110. doi: 10.1016/j.healun.2018.05.004. Epub 2018 May 24.

PMID:
30037729
13.

Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension.

Chemla D, Weatherald J, Lau EMT, Savale L, Boucly A, Attal P, Jaïs X, Parent F, Girerd B, Simonneau G, Montani D, Humbert M, Sitbon O, Hervé P.

Chest. 2018 Oct;154(4):882-892. doi: 10.1016/j.chest.2018.06.015. Epub 2018 Jun 27.

PMID:
29940163
14.

Factors predicting outcome after pulmonary endarterectomy.

Tromeur C, Jaïs X, Mercier O, Couturaud F, Montani D, Savale L, Jevnikar M, Weatherald J, Sitbon O, Parent F, Fabre D, Mussot S, Dartevelle P, Humbert M, Simonneau G, Fadel E.

PLoS One. 2018 Jun 21;13(6):e0198198. doi: 10.1371/journal.pone.0198198. eCollection 2018.

15.

Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, Jevnikar M, Savale L, Jaïs X, Peng M, Simonneau G, Montani D, Humbert M, Sitbon O.

Chest. 2018 Oct;154(4):872-881. doi: 10.1016/j.chest.2018.05.006. Epub 2018 May 22.

PMID:
29800550
16.

Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.

Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, Sitbon O, Jaïs X, Savale L, Weatherald J, Sobanski V, Mathai SC, Shafiq M, Cordier JF, Hachulla E, Simonneau G, Humbert M.

PLoS One. 2018 May 15;13(5):e0197112. doi: 10.1371/journal.pone.0197112. eCollection 2018.

17.

Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension.

Taniguchi Y, Brenot P, Jais X, Garcia C, Weatherald J, Planche O, Fadel E, Humbert M, Simonneau G.

Chest. 2018 Sep;154(3):521-531. doi: 10.1016/j.chest.2018.03.059. Epub 2018 May 3.

18.

[Pulmonary veno-occlusive disease].

Boucly A, Girerd B, Bourlier D, Nemlaghi S, Caliez J, Savale L, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M, Montani D.

Rev Mal Respir. 2018 Feb;35(2):160-170. doi: 10.1016/j.rmr.2017.11.005. Epub 2018 Mar 1. Review. French.

PMID:
29501213
19.

Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry.

Montani D, Henry J, O'Connell C, Jaïs X, Cottin V, Launay D, Habib G, Bourdin A, Jevnikar M, Savale L, Rottat L, Simonneau G, Sitbon O, Humbert M, Allanore Y.

Respiration. 2018;95(4):244-250. doi: 10.1159/000485631. Epub 2018 Feb 28.

20.

RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study.

Hoette S, Creuzé N, Günther S, Montani D, Savale L, Jaïs X, Parent F, Sitbon O, Rochitte CE, Simonneau G, Humbert M, Souza R, Chemla D.

Lung. 2018 Apr;196(2):157-164. doi: 10.1007/s00408-018-0089-7. Epub 2018 Feb 12.

PMID:
29435740
21.

Acute decompensated pulmonary hypertension.

Savale L, Weatherald J, Jaïs X, Vuillard C, Boucly A, Jevnikar M, Montani D, Mercier O, Simonneau G, Fadel E, Sitbon O, Humbert M.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170092. doi: 10.1183/16000617.0092-2017. Print 2017 Dec 31. Review.

22.

Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.

Nossent EJ, Antigny F, Montani D, Bogaard HJ, Ghigna MR, Lambert M, Thomas de Montpréville V, Girerd B, Jaïs X, Savale L, Mercier O, Fadel E, Soubrier F, Sitbon O, Simonneau G, Vonk Noordegraaf A, Humbert M, Perros F, Dorfmüller P.

J Heart Lung Transplant. 2018 May;37(5):647-655. doi: 10.1016/j.healun.2017.09.022. Epub 2017 Oct 4.

PMID:
29108819
23.

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jaïs X, Taniguchi Y, O'Connell C, Parent F, Sattler C, Hervé P, Simonneau G, Montani D, Humbert M, Adir Y, Sitbon O.

Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.

PMID:
29070502
24.

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.

Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L.

Eur Respir J. 2017 Oct 19;50(4). pii: 1700465. doi: 10.1183/13993003.00465-2017. Print 2017 Oct.

25.

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators.

Lancet Respir Med. 2017 Oct;5(10):785-794. doi: 10.1016/S2213-2600(17)30305-3. Epub 2017 Sep 11.

PMID:
28919201
26.

Are indexed values better for defining exercise pulmonary hypertension?

Weatherald J, Boucly A, Lau E, Godinas L, Savale L, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M, Chemla D, Hervé P.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700240. doi: 10.1183/13993003.00240-2017. Print 2017 Sep. No abstract available.

27.

Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry.

Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, Cottin V, Habib G, Prevot G, Chabanne C, Foïs E, Amoura Z, Mouthon L, Le Guern V, Montani D, Simonneau G, Humbert M, Sobanski V, Sitbon O; French Collaborators Recruiting Members(∗).

Chest. 2018 Jan;153(1):143-151. doi: 10.1016/j.chest.2017.08.014. Epub 2017 Aug 26.

PMID:
28851621
28.

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700889. doi: 10.1183/13993003.00889-2017. Print 2017 Aug.

29.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

30.

Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension.

Godinas L, Sattler C, Lau EM, Jaïs X, Taniguchi Y, Jevnikar M, Weatherald J, Sitbon O, Savale L, Montani D, Simonneau G, Humbert M, Laveneziana P, Garcia G.

J Heart Lung Transplant. 2017 Nov;36(11):1234-1242. doi: 10.1016/j.healun.2017.05.024. Epub 2017 May 22.

PMID:
28666570
31.

Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension.

Savale L, Le Pavec J, Mercier O, Mussot S, Jaïs X, Fabre D, O'Connell C, Montani D, Stephan F, Sitbon O, Simonneau G, Dartevelle P, Humbert M, Fadel E.

Ann Thorac Surg. 2017 Aug;104(2):404-411. doi: 10.1016/j.athoracsur.2017.02.034. Epub 2017 May 18.

PMID:
28527964
32.

Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.

Hascoet S, Fournier E, Jaïs X, Le Gloan L, Dauphin C, Houeijeh A, Godart F, Iriart X, Richard A, Radojevic J, Amedro P, Bosser G, Souletie N, Bernard Y, Moceri P, Bouvaist H, Mauran P, Barre E, Basquin A, Karsenty C, Bonnet D, Iserin L, Sitbon O, Petit J, Fadel E, Humbert M, Ladouceur M.

Arch Cardiovasc Dis. 2017 May;110(5):303-316. doi: 10.1016/j.acvd.2017.01.006. Epub 2017 Mar 9.

33.

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.

Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M.

Lancet Respir Med. 2017 Feb;5(2):125-134. doi: 10.1016/S2213-2600(16)30438-6. Epub 2017 Jan 11.

PMID:
28087362
34.

Long-term outcome in liver transplantation candidates with portopulmonary hypertension.

Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, Bouvaist H, Feray C, Borentain P, Jaïs X, Montani D, Parent F, O'Connell C, Hervé P, Humbert M, Simonneau G, Samuel D, Calmus Y, Duvoux C, Durand F, Duclos-Vallée JC, Sitbon O.

Hepatology. 2017 May;65(5):1683-1692. doi: 10.1002/hep.28990. Epub 2017 Mar 14.

PMID:
27997987
35.

Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome.

Hascoët S, Baruteau AE, Humbert M, Simonneau G, Jais X, Petit J, Laux D, Sitbon O, Lambert V, Capderou A.

J Heart Lung Transplant. 2017 Apr;36(4):386-398. doi: 10.1016/j.healun.2016.10.006. Epub 2016 Oct 15.

PMID:
27866929
36.

BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.

Ghigna MR, Guignabert C, Montani D, Girerd B, Jaïs X, Savale L, Hervé P, Thomas de Montpréville V, Mercier O, Sitbon O, Soubrier F, Fadel E, Simonneau G, Humbert M, Dorfmüller P.

Eur Respir J. 2016 Dec;48(6):1668-1681. doi: 10.1183/13993003.00464-2016. Epub 2016 Nov 3.

37.

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.

Riou M, Seferian A, Savale L, Chaumais MC, Guignabert C, Canuet M, Magro P, Rea D, Sitbon O, Jaïs X, Humbert M, Montani D.

Eur Respir J. 2016 Nov;48(5):1517-1519. doi: 10.1183/13993003.01410-2016. Epub 2016 Oct 6. No abstract available.

38.

A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF.

Berthelot E, Montani D, Algalarrondo V, Dreyfuss C, Rifai R, Benmalek A, Jais X, Bouchachi A, Savale L, Simonneau G, Chemla D, Humbert M, Sitbon O, Assayag P.

J Card Fail. 2017 Jan;23(1):29-35. doi: 10.1016/j.cardfail.2016.10.002. Epub 2016 Oct 11.

PMID:
27742455
39.

Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58].

Berger RMF, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M.

Int J Cardiol. 2016 Nov 15;223:1072-1073. doi: 10.1016/j.ijcard.2016.08.333. Epub 2016 Aug 24. No abstract available.

PMID:
27623401
40.

Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.

Pepke-Zaba J, Jais X, Channick R.

Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S248-54. doi: 10.1513/AnnalsATS.201512-802AS. Review.

PMID:
27571006
41.

Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension.

Savale L, Chaumais MC, Montani D, Jaïs X, Hezode C, Antonini TM, Coilly A, Duclos-Vallée JC, Samuel D, Simonneau G, Humbert M, Sitbon O.

Chest. 2016 Jul;150(1):256-8. doi: 10.1016/j.chest.2016.04.031. No abstract available.

PMID:
27396788
42.

Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients.

Boulate D, Mercier O, Mussot S, Fabre D, Stephan F, Haddad F, Jaïs X, Dartevelle P, Fadel E.

Ann Thorac Surg. 2016 Jul;102(1):260-8. doi: 10.1016/j.athoracsur.2016.01.103. Epub 2016 Apr 23.

PMID:
27112656
43.

Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model".

Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D.

Circulation. 2016 Apr 5;133(14):e592-3. doi: 10.1161/CIRCULATIONAHA.116.020946. No abstract available. Erratum in: Circulation. 2016 May 10;133(19):e657-8.

PMID:
27045136
44.

Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure.

Godinas L, Lau EM, Chemla D, Lador F, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G, Humbert M, Hervé P.

Eur Respir J. 2016 Jul;48(1):254-7. doi: 10.1183/13993003.01678-2015. Epub 2016 Mar 30. No abstract available.

45.

Pulmonary veno-occlusive disease.

Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, Perros F, Nossent E, Garcia G, Parent F, Fadel E, Soubrier F, Sitbon O, Simonneau G, Humbert M.

Eur Respir J. 2016 May;47(5):1518-34. doi: 10.1183/13993003.00026-2016. Epub 2016 Mar 23. Review.

46.

Initial dual oral combination therapy in pulmonary arterial hypertension.

Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jaïs X, De Groote P, Chaouat A, Chabannes C, Bergot E, Bouvaist H, Dauphin C, Bourdin A, Bauer F, Montani D, Humbert M, Simonneau G.

Eur Respir J. 2016 Jun;47(6):1727-36. doi: 10.1183/13993003.02043-2015. Epub 2016 Mar 17.

47.

Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension.

Godinas L, Amar D, Montani D, Lau EM, Jaïs X, Savale L, Jevnikar M, Sitbon O, Simonneau G, Humbert M, Laveneziana P, Garcia G.

J Heart Lung Transplant. 2016 May;35(5):647-56. doi: 10.1016/j.healun.2015.12.022. Epub 2016 Jan 6.

PMID:
26987595
48.

Health-related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross-sectional ACHILLE study.

Amedro P, Basquin A, Gressin V, Clerson P, Jais X, Thambo JB, Guerin P, Cohen S, Bonnet D.

Cardiol Young. 2016 Oct;26(7):1250-9. doi: 10.1017/S1047951116000056. Epub 2016 Mar 16.

PMID:
26980152
49.

Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics.

Lau EM, Godinas L, Sitbon O, Montani D, Savale L, Jaïs X, Lador F, Gunther S, Celermajer DS, Simonneau G, Humbert M, Chemla D, Herve P.

Eur Respir J. 2016 May;47(5):1436-44. doi: 10.1183/13993003.01684-2015. Epub 2016 Mar 10.

50.

A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica.

Bourlier D, O'Connell C, Montani D, Savale L, Seferian A, Parent F, Humbert M, Simonneau G, Sitbon O, Jaïs X.

Eur Respir Rev. 2016 Mar;25(139):93-6. doi: 10.1183/16000617.0073-2015. No abstract available.

Supplemental Content

Support Center